Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.33 |
| ▸ | BUB1 | O43683 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14719623 | 1.00 | USP2 (0.35) | USP2SMN1; SMN2NR1H2DDB1CRBN | |
| SCHEMBL14719036 | 0.78 | DDB1 (0.34) | USP2SMN1; SMN2NR1H2DDB1CRBN | |
| SCHEMBL14719034 | 0.78 | DDB1 (0.34) | USP2SMN1; SMN2NR1H2DDB1CRBN | |
| SCHEMBL14719429 | 0.75 | USP2 (0.42) | USP2SMN1; SMN2NR1H2DDB1CRBN | |
| SCHEMBL31080015 | 0.68 | USP2 (0.50) | USP2SMN1; SMN2NR1H2DDB1CRBN | |
| SCHEMBL13801225 | 0.68 | USP2 (0.50) | USP2SMN1; SMN2NR1H2 | |
| SCHEMBL14719273 | 0.68 | USP2 (0.45) | USP2SMN1; SMN2NR1H2 | |
| SCHEMBL14718602 | 0.67 | USP2 (0.40) | USP2SMN1; SMN2NR1H2DDB1CRBN | |
| SCHEMBL14719295 | 0.66 | USP30 (0.44) | DDB1CRBN | |
| SCHEMBL17081081 | 0.64 | USP2 (0.42) | USP2SMN1; SMN2NR1H2DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102683-B2 | Heterocyclic compounds | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2015-08-11 | — | — | US | disclosed |
| US-20130053553-A1 | HETEROCYCLIC COMPOUNDS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053553-A1 | HETEROCYCLIC COMPOUNDS | CYP2C8, UGT1A8, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | USP2 3214/4885SMN1; SMN2 3065/4885NR1H2 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.